78 related articles for article (PubMed ID: 12201644)
1. Docetaxel/platinum combination provides quality-of-life advantage over vinorelbine/cisplatin in advanced lung cancer.
Oncology (Williston Park); 2002 Aug; 16(8):1052. PubMed ID: 12201644
[No Abstract] [Full Text] [Related]
2. Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non--small cell lung cancer: interim analysis.
Belani C;
Semin Oncol; 2001 Jun; 28(3 Suppl 9):10-4. PubMed ID: 11441409
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel combination produces 2-year survival advantage in NSCLC patients.
Oncology (Williston Park); 2001 Dec; 15(12):1559, 1564. PubMed ID: 11780700
[No Abstract] [Full Text] [Related]
4. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
Fossella F; Pereira JR; von Pawel J; Pluzanska A; Gorbounova V; Kaukel E; Mattson KV; Ramlau R; Szczesna A; Fidias P; Millward M; Belani CP
J Clin Oncol; 2003 Aug; 21(16):3016-24. PubMed ID: 12837811
[TBL] [Abstract][Full Text] [Related]
5. [Chemotherapy for elderly patients with lung cancer].
Okamoto H; Watanabe K
Nihon Rinsho; 2002 May; 60 Suppl 5():591-5. PubMed ID: 12101743
[No Abstract] [Full Text] [Related]
6. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
[TBL] [Abstract][Full Text] [Related]
7. Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
Aapro MS
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):46-9. PubMed ID: 9364543
[TBL] [Abstract][Full Text] [Related]
8. New options in the treatment of non-small cell lung cancer.
Fossella F; Rigas JR; Belani CP
Anticancer Drugs; 1999 Nov; 10 Suppl 1():S25-8. PubMed ID: 10630365
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
[TBL] [Abstract][Full Text] [Related]
10. Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines.
Aoe K; Kiura K; Ueoka H; Tabata M; Matsumura T; Chikamori M; Matsushita A; Kohara H; Harada M
Anticancer Res; 1999; 19(1A):291-9. PubMed ID: 10226557
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel in the management of advanced non-small cell lung cancer.
Miller VA
Semin Oncol; 1998 Jun; 25(3 Suppl 8):15-9. PubMed ID: 9704671
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
Belani CP
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer.
Mattson K; Saarinen A; Jekunen A
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-5-S14-8. PubMed ID: 9335516
[TBL] [Abstract][Full Text] [Related]
14. Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial.
Belani CP; Pereira JR; von Pawel J; Pluzanska A; Gorbounova V; Kaukel E; Mattson KV; Ramlau R; Szczesna A; Fidias P; Millward M; Fossella F;
Lung Cancer; 2006 Aug; 53(2):231-9. PubMed ID: 16787687
[TBL] [Abstract][Full Text] [Related]
15. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
Ramsey SD; Moinpour CM; Lovato LC; Crowley JJ; Grevstad P; Presant CA; Rivkin SE; Kelly K; Gandara DR
J Natl Cancer Inst; 2002 Feb; 94(4):291-7. PubMed ID: 11854391
[TBL] [Abstract][Full Text] [Related]
16. Re: Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
Malayeri R
J Natl Cancer Inst; 2002 Aug; 94(15):1172; author reply 1172. PubMed ID: 12165643
[No Abstract] [Full Text] [Related]
17. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
Khuri FR
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):53-62. PubMed ID: 12108898
[TBL] [Abstract][Full Text] [Related]
18. Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer.
Krug LM; Miller VA
Semin Oncol; 1999 Oct; 26(5 Suppl 16):24-6; discussion 41-2. PubMed ID: 10585005
[TBL] [Abstract][Full Text] [Related]
19. Study shows 2-year survival advantage for docetaxel.
Expert Rev Anticancer Ther; 2001 Oct; 1(3):323-4. PubMed ID: 12113094
[No Abstract] [Full Text] [Related]
20. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
Belani CP; Fossella F
Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
